Pentraxin 3 as a novel diagnostic marker in neonatal sepsis.
Biomarkers
/ metabolism
C-Reactive Protein
/ metabolism
Case-Control Studies
Female
Humans
Infant, Newborn
Inflammation Mediators
/ metabolism
Intensive Care, Neonatal
Male
Neonatal Sepsis
/ metabolism
Predictive Value of Tests
Prospective Studies
ROC Curve
Serum Amyloid P-Component
/ metabolism
Signal Transduction
/ immunology
Diagnosis
marker
neonate
pentraxin 3
sepsis
Journal
Journal of neonatal-perinatal medicine
ISSN: 1878-4429
Titre abrégé: J Neonatal Perinatal Med
Pays: Netherlands
ID NLM: 101468335
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
6
8
2019
medline:
22
7
2020
entrez:
6
8
2019
Statut:
ppublish
Résumé
Neonatal sepsis is an important cause of morbidity and mortality especially in developing countries. As clinical manifestations of neonatal sepsis are nonspecific, early diagnosis and treatment remain a challenge. Pentraxin 3 (PTX3) is an acute-phase protein secreted by various cells in response to the proinflammatory signals. Our aim was to investigate the diagnostic value of PTX3 in neonatal sepsis. We studied 90 neonates; 60 with culture-proven sepsis and 30 healthy neonates as a control group. Serum levels of PTX 3 were measured by ELISA. Neonates with sepsis had significantly higher levels of PTX 3 as compared to controls (p < 0.001). Diagnostic cutoff value of PTX 3 was 5.6 μg/L with a sensitivity of 98.3% and a specificity of 96.7%. PTX 3 was significantly increased in nonsurvivors when compared to survivors (p < 0.001). PTX3 had better sensitivity when compared with CRP. PTX 3 could be used as a new biomarker of neonatal sepsis with high sensitivity and specificity.
Sections du résumé
BACKGROUND
BACKGROUND
Neonatal sepsis is an important cause of morbidity and mortality especially in developing countries. As clinical manifestations of neonatal sepsis are nonspecific, early diagnosis and treatment remain a challenge. Pentraxin 3 (PTX3) is an acute-phase protein secreted by various cells in response to the proinflammatory signals. Our aim was to investigate the diagnostic value of PTX3 in neonatal sepsis.
METHODS
METHODS
We studied 90 neonates; 60 with culture-proven sepsis and 30 healthy neonates as a control group. Serum levels of PTX 3 were measured by ELISA.
RESULTS
RESULTS
Neonates with sepsis had significantly higher levels of PTX 3 as compared to controls (p < 0.001). Diagnostic cutoff value of PTX 3 was 5.6 μg/L with a sensitivity of 98.3% and a specificity of 96.7%. PTX 3 was significantly increased in nonsurvivors when compared to survivors (p < 0.001). PTX3 had better sensitivity when compared with CRP.
CONCLUSION
CONCLUSIONS
PTX 3 could be used as a new biomarker of neonatal sepsis with high sensitivity and specificity.
Identifiants
pubmed: 31381534
pii: NPM190261
doi: 10.3233/NPM-190261
doi:
Substances chimiques
Biomarkers
0
Inflammation Mediators
0
Serum Amyloid P-Component
0
PTX3 protein
148591-49-5
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM